D'Silva H, Munger W, Cohen M C, Cohen S
Clin Immunol Immunopathol. 1985 Mar;34(3):326-32. doi: 10.1016/0090-1229(85)90181-3.
A lymphokine, tumor migration inhibition factor (TMIF), that can inhibit the migration of tumor cells in vitro without cytotoxic effect has been described. TMIF can be produced in vitro or in vivo. In the present study, it is demonstrated that administration of TMIF can lead to a transient decrease in recoverable tumor cells from the peritoneal cavities of otherwise untreated mice. This result, which appears to be due to a direct effect of the mediator, rather than a consequence of inflammatory cell accumulation, is analogous to the effect of macrophage migration inhibition factor (MIF) on macrophages in the well known macrophage disappearance reaction. These findings demonstrate that TMIF can exert an effect in vivo predicted from its in vitro properties, and raise the possibility that this effect can be exploited in an appropriate therapeutic model.
一种淋巴因子，即肿瘤迁移抑制因子（TMIF），已被报道其能够在无细胞毒性作用的情况下抑制肿瘤细胞在体外的迁移。TMIF可在体外或体内产生。在本研究中，已证实给予TMIF可导致原本未经治疗的小鼠腹腔内可回收肿瘤细胞短暂减少。这一结果似乎是由于该介质的直接作用，而非炎性细胞聚集的结果，类似于在著名的巨噬细胞消失反应中巨噬细胞迁移抑制因子（MIF）对巨噬细胞的作用。这些发现表明，TMIF能够在体内发挥其体外特性所预测的作用，并增加了这种作用可在适当的治疗模型中得到应用的可能性。
